CoChat

Polyethylene glycol immunogenicity in nanomedicine

Chen, Yunching, Su, Yu-Cheng, Roffler, Steve R. · 2025 · Nature Reviews Bioengineering
Cited by 113

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s44222-025-00321-6

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 222

  1. Davis, F. F. The origin of pegnology. Adv. Drug Deliv. Rev. 54, 457–458 (2002). · DOI · Paper page
  2. Gao, Y., Joshi, M., Zhao, Z. & Mitragotri, S. PEGylated therapeutics in the clinic. Bioeng. Transl. Med. 9, e10600 (2024). · DOI · Paper page
  3. Arturson, P., Laakso, T. & Edman, P. Acrylic microspheres in vivo IX: blood elimination kinetics and organ distribution of microparticles with different surface characteristics. J. Pharm. Sci. 72, 1415–1420 (1983). · DOI
  4. Klibanov, A. L., Maruyama, K., Torchilin, V. P. & Huang, L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268, 235–237 (1990). · DOI · Paper page
  5. López-Estevez, A. M., Gref, R. & Alonso, M. J. A journey through the history of PEGylated drug delivery nanocarriers. Drug Deliv. Transl. Res. 14, 1–6 (2024). · DOI
  6. Du, X. J. et al. Regulating the surface poly(ethylene glycol) density of polymeric nanoparticles and evaluating its role in drug delivery in vivo. Biomaterials 69, 1–11 (2015). · DOI
  7. Chen, B.-M. et al. Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals. Anal. Chem. 88, 10661–10666 (2016). This article reports detailed assay validation and measurement of pre-existing anti-PEG antibodies in a large cohort of healthy donors. · DOI · Paper page
  8. Yang, Q. et al. Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population. Anal. Chem. 88, 11804–11812 (2016). · DOI · Paper page
  9. Ju, Y. et al. Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine. ACS Nano 16, 11769–11780 (2022). This article reports that COVID 19 mRNA vaccines can increase the concentrations of both anti-PEG IgG and IgM antibodies. · DOI · Paper page
  10. Chen, B. M., Cheng, T. L. & Roffler, S. R. Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies. ACS Nano 15, 14022–14048 (2021). This review discusses PEG immunogenicity and anti-PEG antibodies. · DOI · Paper page
  11. Bavli, Y. et al. Anti-PEG antibodies before and after a first dose of Comirnaty® (mRNA-LNP-based SARS-CoV-2 vaccine). J. Control. Rel. 354, 316–322 (2023). · DOI
  12. Tenchov, R., Sasso, J. M. & Zhou, Q. A. PEGylated lipid nanoparticle formulations: immunological safety and efficiency perspective. Bioconjug. Chem. 34, 941–960 (2023). · DOI · Paper page
  13. Fu, J., Wu, E., Li, G., Wang, B. & Zhan, C. Anti-PEG antibodies: current situation and countermeasures. Nano Today 55, 102163 (2024). · DOI
  14. Gaballa, S. A. et al. Treatment-induced and pre-existing anti-PEG antibodies: prevalence, clinical implications, and future perspectives. J. Pharm. Sci. 113, 555–578 (2024). · DOI
  15. Simberg, D. & Moghimi, S. M. Anti-poly (ethylene glycol)(PEG) antibodies: from where are we coming and where are we going. J. Nanotheranos. 5, 99–103 (2024). · DOI
  16. Lee, C.-C. et al. Structural basis of polyethylene glycol recognition by antibody. J. Biomed. Sci. 27, 1–13 (2020). · DOI · Paper page
  17. Huckaby, J. T. et al. Structure of an anti-PEG antibody reveals an open ring that captures highly flexible PEG polymers. Commun. Chem. 3, 124 (2020). · DOI
  18. Nguyen, M.-T. T. et al. Structural determination of an antibody that specifically recognizes polyethylene glycol with a terminal methoxy group. Commun. Chem. 5, 88 (2022). · DOI
  19. Su, Y. C. et al. Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy. Nat. Commun. 8, 15507 (2017). This article reports that pre-targeting bispecific PEG engagers to cancer cells can enhance internalization and efficacy of PEGylated nanomedicines. · DOI · Paper page
  20. Chang, T.-C., Chen, B.-M., Wu, J.-Y., Cheng, T.-L. & Roffler, S. Impact of anti-PEG antibody affinity on accelerated blood clearance of pegylated epoetin beta in mice. Biomed. Pharmacother. 146, 112502 (2022). · DOI
  21. Hsiao, C. Y. et al. Engineering a high-affinity anti-methoxy poly(ethylene glycol) (mPEG) antibody for sensitive immunosensing of mPEGylated therapeutics and mPEG molecules. Bioconjug. Chem. 33, 2180–2188 (2022). · DOI
  22. Su, Y. C., Chen, B. M., Chuang, K. H., Cheng, T. L. & Roffler, S. R. Sensitive quantification of PEGylated compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies. Bioconjug. Chem. 21, 1264–1270 (2010). · DOI · Paper page
  23. Mima, Y., Hashimoto, Y., Shimizu, T., Kiwada, H. & Ishida, T. Anti-PEG IgM is a major contributor to the accelerated blood clearance of polyethylene glycol-conjugated protein. Mol. Pharm. 12, 2429–2435 (2015). · DOI · Paper page
  24. Kozma, G. T. et al. Pseudo-anaphylaxis to polyethylene glycol (PEG)-coated liposomes: roles of anti-PEG IgM and complement activation in a porcine model of human infusion reactions. ACS Nano 13, 9315–9324 (2019). · DOI · Paper page
  25. Moghimi, S. M. et al. Perspectives on complement and phagocytic cell responses to nanoparticles: from fundamentals to adverse reactions. J. Control. Rel. 356, 115–129 (2023). · DOI
  26. Liu, Y. et al. The strategy used by naïve anti-PEG antibodies to capture flexible and featureless PEG chains. J. Control. Rel. 380, 396–403 (2025). · doi:10.1016/j.jconrel.2025.02.001
  27. Povsic, T. J. et al. Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer. J. Allergy Clin. Immunol. 138, 1712–1715 (2016). · DOI · Paper page
  28. Sellaturay, P., Nasser, S., Islam, S., Gurugama, P. & Ewan, P. W. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID‐19 vaccine. Clin. Exp. Allergy 51, 861 (2021). · DOI · Paper page
  29. Chen, B.-M. et al. Liposomes with low levels of grafted poly(ethylene glycol) remain susceptible to destabilization by anti-poly(ethylene glycol) antibodies. ACS Nano 18, 22122–22138 (2024). · DOI
  30. Chen, E. et al. Premature drug release from polyethylene glycol (PEG)-coated liposomal doxorubicin via formation of the membrane attack complex. ACS Nano 14, 7808–7822 (2020). · DOI · Paper page
  31. Li, Y. et al. Complement opsonization of nanoparticles: differences between humans and preclinical species. J. Control. Rel. 338, 548–556 (2021). · DOI
  32. Chen, W.-A. et al. Antibodies against poly (ethylene glycol) activate innate immune cells and induce hypersensitivity reactions to PEGylated nanomedicines. ACS Nano 17, 5757–5772 (2023). This article reports the mechanism of hypersensitivity reactions induced by anti-PEG IgG antibodies against nanomedicines. · DOI
  33. Warren, C. M. et al. Assessment of allergic and anaphylactic reactions to mRNA COVID-19 vaccines with confirmatory testing in a US regional health system. JAMA Netw. Open 4, e2125524 (2021). · DOI · Paper page
  34. Troelnikov, A. et al. Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy. J. Allergy Clin. Immunol. 148, 91–95 (2021). · DOI
  35. Mouri, M. et al. Serum polyethylene glycol-specific IgE and IgG in patients with hypersensitivity to COVID-19 mRNA vaccines. Allergol. Int. 71, 512–519 (2022). · DOI
  36. Kan, A. K. C., Chiang, V., Ip, W. K., Au, E. Y. & Li, P. H. Anti‐polyethylene glycol (PEG) antibody isotypes may predict PEG‐associated allergy and COVID‐19 protection among patients with history of suspected COVID‐19 vaccine allergy. Clin. Transl. Allergy 13, e12284 (2023). · doi:10.1002/clt2.12284
  37. Prussin, C. & Metcalfe, D. D. IgE, mast cells, basophils, and eosinophils. J. Allergy Clin. Immunol. 111, S486–S494 (2003). · DOI · Paper page
  38. Zhou, Z.-H. et al. Anti-PEG IgE in anaphylaxis associated with polyethylene glycol. J. Allergy Clin. Immunol. Pract. 9, 1731–1733.e3 (2021). · DOI · Paper page
  39. Lubich, C. et al. The mystery of antibodies against polyethylene glycol (PEG) — what do we know? Pharm. Res. 33, 2239–2249 (2016). · DOI · Paper page
  40. Deuker, M. F., Mailänder, V., Morsbach, S. & Landfester, K. Anti-PEG antibodies enriched in the protein corona of PEGylated nanocarriers impact the cell uptake. Nanoscale Horiz. 8, 1377–1385 (2023). · DOI
  41. Ibrahim, M. et al. Investigation of anti-PEG antibody response to PEG-containing cosmetic products in mice. J. Control. Rel. 354, 260–267 (2023). · DOI
  42. Chang, C.-J. et al. A genome-wide association study identifies a novel susceptibility locus for the immunogenicity of polyethylene glycol. Nat. Commun. 8, 522 (2017). · DOI · Paper page
  43. Shen, L. et al. Free PEG suppresses anaphylaxis to PEGylated nanomedicine in swine. ACS Nano 18, 8733–8744 (2024). This article reports that free PEG can help block hypersensitivity reactions caused by anti-PEG antibodies in a large animal model. · DOI
  44. Stavnsbjerg, C. et al. Accelerated blood clearance and hypersensitivity by PEGylated liposomes containing TLR agonists. J. Control. Rel. 342, 337–344 (2022). · DOI
  45. Guerrini, G. et al. Monitoring anti-PEG antibodies level upon repeated lipid nanoparticle-based COVID-19 vaccine administration. Int. J. Mol. Sci. 23, 8838 (2022). · DOI · Paper page
  46. Kozma, G. T. et al. Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing COVID-19 vaccines: evidence for immunogenicity of PEG. Vaccine 41, 4561–4570 (2023). · DOI · Paper page
  47. Li, Y. et al. Optimized enzyme-linked immunosorbent assay for anti-PEG antibody detection in healthy donors and patients treated with PEGylated liposomal doxorubicin. Mol. Pharm. 21, 3053–3060 (2024). · DOI
  48. Moghimi, S. M. The effect of methoxy-PEG chain length and molecular architecture on lymph node targeting of immuno-PEG liposomes. Biomaterials 27, 136–144 (2006). · DOI
  49. Reddy, S. T. et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 25, 1159–1164 (2007). · DOI · Paper page
  50. Nakamura, T. et al. The effect of size and charge of lipid nanoparticles prepared by microfluidic mixing on their lymph node transitivity and distribution. Mol. Pharm. 17, 944–953 (2020). · DOI · Paper page
  51. Lee, Y. et al. Development of lipid nanoparticle formulation for the repeated administration of mRNA therapeutics. Biomater. Res. 28, 0017 (2024). · DOI
  52. Kavita, U., Miller, W., Ji, Q. C. & Pillutla, R. C. A fit-for-purpose method for the detection of human antibodies to surface-exposed components of BMS-986263, a lipid nanoparticle-based drug product containing a siRNA drug substance. AAPS J. 21, 1–13 (2019). · DOI
  53. Lin, Y. C. et al. Accelerated clearance by antibodies against methoxy PEG depends on pegylation architecture. J. Control. Rel. 354, 354–367 (2023). · DOI
  54. Li, Z. et al. Development of anti-PEG IgG/IgM/IgE ELISA assays for profiling anti-PEG immunoglobulin response in PEG-sensitized individuals and patients with alpha-gal allergy. J. Control. Rel. 366, 342–348 (2024). · DOI
  55. Pengo, V., Biasiolo, A., Bison, E., Chantarangkul, V. & Tripodi, A. Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-β2-glycoprotein I activity. Thromb. Res. 120, 127–133 (2007). · DOI
  56. Moghimi, S. M., Simberg, D., Skotland, T., Yaghmur, A. & Hunter, A. C. The interplay between blood proteins, complement, and macrophages on nanomedicine performance and responses. J. Pharmacol. Exp. Ther. 370, 581–592 (2019). · DOI · Paper page
  57. Moghimi, S. M., Simberg, D., Papini, E. & Farhangrazi, Z. S. Complement activation by drug carriers and particulate pharmaceuticals: principles, challenges and opportunities. Adv. Drug Deliv. Rev. 157, 83–95 (2020). · DOI
  58. Vu, V. P. et al. Immunoglobulin deposition on biomolecule corona determines complement opsonization efficiency of preclinical and clinical nanoparticles. Nat. Nanotechnol. 14, 260–268 (2019). · DOI · Paper page
  59. Li, Y. et al. Inhibition of acute complement responses towards bolus-injected nanoparticles using targeted short-circulating regulatory proteins. Nat. Nanotechnol. 19, 246–254 (2024). This article reports the design of recombinant complement inhibitors to improve nanomedicine efficacy and safety. · DOI
  60. Li, Y. et al. Nanoparticle-binding immunoglobulins predict variable complement responses in healthy and diseased cohorts. ACS Nano 18, 28649–28658 (2024). · DOI
  61. Mak, T. W. & Saunders, M. E. The Immune Response: Basic and Clinical Principles (Academic Press, 2005).
  62. Pedersen, M. B. et al. Curvature of synthetic and natural surfaces is an important target feature in classical pathway complement activation. J. Immunol. 184, 1931–1945 (2010). · DOI · Paper page
  63. Feinstein, A., Richardson, N. & Taussig, M. I. Immunoglobulin flexibility in complement activation. Immunol. Today 7, 169–174 (1986). · DOI
  64. Lachmann, P. J. Looking back on the alternative complement pathway. Immunobiology 223, 519–523 (2018). · DOI
  65. Nagayama, S., Ogawara, K.-I, Fukuoka, Y., Higaki, K. & Kimura, T. Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics. Int. J. Pharm. 342, 215–221 (2007). · DOI · Paper page
  66. Aragnol, D. & Leserman, L. D. Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo. Proc. Natl Acad. Sci. USA 83, 2699–2703 (1986). · DOI · Paper page
  67. Ishida, T. et al. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J. Control. Rel. 112, 15–25 (2006). · DOI · Paper page
  68. Ishida, T. & Kiwada, H. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int. J. Pharm. 354, 56–62 (2008). · DOI · Paper page
  69. Lin, S. et al. Reexamining in vivo fate of paclitaxel-loaded polymeric micelles. Nano Today 56, 102255 (2024). · DOI
  70. Hsieh, Y. C. et al. Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes. Theranostics 8, 3164–3175 (2018). · DOI · Paper page
  71. Chang, T. C. et al. Both IgM and IgG antibodies against polyethylene glycol can alter the biological activity of methoxy polyethylene glycol-epoetin beta in mice. Pharmaceutics 12, 15 (2019). · DOI
  72. Omata, D. et al. Effect of anti-PEG antibody on immune response of mRNA-loaded lipid nanoparticles. Mol. Pharm. 21, 5672–5680 (2024). · DOI
  73. Yang, M. et al. Effects of PEG antibodies on in vivo performance of LNP-mRNA vaccines. Int. J. Pharm. 650, 123695 (2024). · DOI
  74. Liu, Y.-L. et al. Impact of pre-existing anti-polyethylene glycol antibodies on the pharmacokinetics and efficacy of a COVID-19 mRNA vaccine (Comirnaty) in vivo. Biomater. Res. 28, 0112 (2024). · DOI
  75. Senti, M. E. et al. Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement. J. Control. Rel. 341, 475–486 (2022). · DOI · Paper page
  76. Semple, S. C. et al. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol–lipid conjugates and nucleic acid. J. Pharmacol. Exp. Ther. 312, 1020–1026 (2005). · DOI · Paper page
  77. Judge, A., McClintock, K., Phelps, J. R. & MacLachlan, I. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol. Ther. 13, 328–337 (2006). · DOI · Paper page
  78. Kikuchi, Y. & Kaplan, A. P. A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria. J. Allergy Clin. Immunol. 109, 114–118 (2002). · DOI · Paper page
  79. El-Lati, S. G., Church, M. K. & Dahinden, C. A. Complement peptides C3a- and C5a-induced mediator release from dissociated human skin mast cells. J. Invest. Dermatol. 102, 803–806 (1994). · DOI · Paper page
  80. Guo, R.-F. & Ward, P. A. Role of C5a in inflammatory responses. Annu. Rev. Immunol. 23, 821–852 (2005). · DOI · Paper page
  81. Jönsson, F. et al. An IgG-induced neutrophil activation pathway contributes to human drug-induced anaphylaxis. Sci. Transl. Med. 11, eaat1479 (2019). · DOI · Paper page
  82. Vultaggio, A. et al. Manifestations of antidrug antibodies response: hypersensitivity and infusion reactions. J. Interferon Cytokine Res. 34, 946–952 (2014). · DOI
  83. Weber, F. et al. First infusion reactions are mediated by FcγRIIIb and neutrophils. Pharm. Res. 35, 1–11 (2018). · DOI
  84. Jönsson, F. et al. Mouse and human neutrophils induce anaphylaxis. J. Clin. Invest. 121, 1484–1496 (2011). · DOI · Paper page
  85. Moghimi, S. M. & Simberg, D. Translational gaps in animal models of human infusion reactions to nanomedicines. Nanomedicine 13, 973–975 (2018). · doi:10.2217/nnm-2018-0064
  86. Ong, G. L. & Mattes, M. J. Mouse strains with typical mammalian levels of complement activity. J. Immunol. Methods 125, 147–158 (1989). · DOI
  87. Beutier, H. et al. Platelets expressing IgG receptor FcγRIIA/CD32A determine the severity of experimental anaphylaxis. Sci. Immunol. 3, eaan5997 (2018). · DOI
  88. Li, S. et al. Voluntary‐opsonization‐enabled precision nanomedicines for inflammation treatment. Adv. Mater. 33, 2006160 (2021). · DOI
  89. Armstrong, R. A. Alzheimer’s disease and the eye. J. Optom. 2, 103–111 (2009). · DOI · Paper page
  90. Lipsky, P. E. et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res. Ther. 16, 1–8 (2014). · DOI · Paper page
  91. Gupta, S. et al. Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials. eBioMedicine 37, 366–373 (2018). · DOI
  92. Takata, H. et al. Anti-PEG IgM production induced by PEGylated liposomes as a function of administration route. J. Control. Rel. 360, 285–292 (2023). This article demonstrates the effect of administration routes on the production of anti-PEG antibodies induced by PEGylated liposomes. · DOI
  93. Grenier, P., Chenard, V. & Bertrand, N. The mechanisms of anti-PEG immune response are different in the spleen and the lymph nodes. J. Control. Rel. 353, 611–620 (2023). · DOI
  94. Münter, R., Christensen, E., Andresen, T. L. & Larsen, J. B. Studying how administration route and dose regulates antibody generation against LNPs for mRNA delivery with single-particle resolution. Mol. Ther. Methods Clin. Dev. 29, 450–459 (2023). · DOI
  95. Kagan, L. et al. The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model. Eur. J. Pharm. Biopharm. 67, 759–765 (2007). · DOI
  96. Wang, H. et al. Polyethylene glycol (PEG)-associated immune responses triggered by clinically relevant lipid nanoparticles in rats. npj Vaccines 8, 169 (2023). · DOI
  97. Kent, S. J. et al. Blood distribution of SARS-CoV-2 lipid nanoparticle mRNA vaccine in humans. ACS Nano 18, 27077–27089 (2024). · DOI
  98. McSweeney, M. D. et al. Overcoming anti-PEG antibody mediated accelerated blood clearance of PEGylated liposomes by pre-infusion with high molecular weight free PEG. J. Control. Rel. 311, 138–146 (2019). · DOI
  99. McSweeney, M. D. et al. Pre-treatment with high molecular weight free PEG effectively suppresses anti-PEG antibody induction by PEG-liposomes in mice. J. Control. Rel. 329, 774–781 (2021). · DOI
  100. Fletcher, A. M. et al. Adverse vacuolation in multiple tissues in cynomolgus monkeys following repeat-dose administration of a PEGylated protein. Toxicol. Lett. 317, 120–129 (2019). · DOI
  101. Chiang, V. et al. Polyethylene glycol allergy: risks of skin testing and complement-mediated anaphylaxis. J. Investig. Allergol. Clin. Immunol. 71–73 (2023). · doi:10.18176/jiaci.0813
  102. Hamad, I., Hunter, A., Szebeni, J. & Moghimi, S. M. Poly (ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol. Immunol. 46, 225–232 (2008). · DOI · Paper page
  103. Liu, M. et al. Branched PEG-modification: a new strategy for nanocarriers to evade of the accelerated blood clearance phenomenon and enhance anti-tumor efficacy. Biomaterials 283, 121415 (2022). · DOI
  104. Liu, M. et al. ‘Y-type’ PEG modified liposomes could eliminate the accelerated blood clearance (ABC) phenomenon and improved tumor therapy. Appl. Mater. Today 32, 101853 (2023). · DOI
  105. Maiti, D., Yokoyama, M. & Shiraishi, K. Impact of the hydrophilicity of poly (sarcosine) on poly (ethylene glycol)(PEG) for the suppression of anti-PEG antibody binding. ACS Omega 9, 34577–34588 (2024). · DOI
  106. Xu, H., Wang, K. Q., Deng, Y. H. & Chen, D. W. Effects of cleavable PEG-cholesterol derivatives on the accelerated blood clearance of PEGylated liposomes. Biomaterials 31, 4757–4763 (2010). · DOI
  107. Suzuki, T. et al. PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: faster PEG shedding attenuates anti-PEG IgM production. Int. J. Pharm. 588, 119792 (2020). · DOI · Paper page
  108. Sui, D. et al. Cleavable-branched polymer-modified liposomes reduce accelerated blood clearance and enhance photothermal therapy. ACS Appl. Mater. Interfaces 15, 32110–32120 (2023). · DOI
  109. Pannuzzo, M. et al. Overcoming nanoparticle-mediated complement activation by surface PEG pairing. Nano Lett. 20, 4312–4321 (2020). · DOI · Paper page
  110. Tian, Y. et al. Engineering poly (ethylene glycol) nanoparticles for accelerated blood clearance inhibition and targeted drug delivery. J. Am. Chem. Soc. 144, 18419–18428 (2022). · DOI
  111. Meszaros, T. et al. Factor H inhibits complement activation induced by liposomal and micellar drugs and the therapeutic antibody rituximab in vitro. Nanomedicine 12, 1023–1031 (2016). · DOI
  112. Wang, Z. et al. Combating complement’s deleterious effects on nanomedicine by conjugating complement regulatory proteins to nanoparticles. Adv. Mater. 34, 2107070 (2022). · DOI
  113. Park, J. H. et al. Cloaking silica nanoparticles with functional protein coatings for reduced complement activation and cellular uptake. ACS Nano 14, 11950–11961 (2020). · DOI · Paper page
  114. Duong, B. H. et al. Decoration of T-independent antigen with ligands for CD22 and Siglec-G can suppress immunity and induce B cell tolerance in vivo. J. Exp. Med. 207, 173 (2010). · DOI · Paper page
  115. Macauley, M. S. et al. Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis. J. Clin. Invest. 123, 3074–3083 (2013). · DOI · Paper page
  116. Qian, H. et al. Recent advances on next generation of polyzwitterion-based nano-vectors for targeted drug delivery. J. Control. Rel. 343, 492–505 (2022). · DOI
  117. Overby, C., Park, S., Summers, A. & Benoit, D. S. W. Zwitterionic peptides: tunable next-generation stealth nanoparticle modifications. Bioact. Mater. 27, 113–124 (2023).
  118. Banskota, S. et al. Genetically encoded stealth nanoparticles of a zwitterionic polypeptide–paclitaxel conjugate have a wider therapeutic window than Abraxane in multiple tumor models. Nano Lett. 20, 2396–2409 (2020). · DOI
  119. Jackson, M. A. et al. Zwitterionic nanocarrier surface chemistry improves siRNA tumor delivery and silencing activity relative to polyethylene glycol. ACS Nano 11, 5680–5696 (2017). This article demonstrates the potential of zwitterionic polymers as PEG alternatives for the creation of stealth nanomedicines. · DOI
  120. Lee, J. et al. Ultrastable and redispersible zwitterionic bottlebrush micelles for drug delivery. ACS Appl. Mater. Interfaces 16, 55118–55129 (2024).
  121. Moitra, P. et al. Context-responsive nanoparticle derived from synthetic zwitterionic ionizable phospholipids in targeted CRISPR/Cas9 therapy for basal-like breast cancer. ACS Nano 18, 9199–9220 (2024). · DOI
  122. Zhang, Z., Sun, H., Giannino, J., Wu, Y. & Cheng, C. Biodegradable zwitterionic polymers as PEG alternatives for drug delivery. J. Polym. Sci. 62, 2231–2250 (2024). · DOI
  123. Najmina, M. et al. A stealthiness evaluation of main chain carboxybetaine polymer modified into liposome. Pharmaceutics 16, 1271 (2024). · DOI
  124. Sanchez, A. et al. Substituting poly(ethylene glycol) lipids with poly(2-ethyl-2-oxazoline) lipids improves lipid nanoparticle repeat dosing. Adv. Healthc. Mater. 13, e2304033 (2024). · DOI
  125. Rajesh, S. et al. Lipidic poly (2-oxazoline)s as PEG replacement steric stabilisers for cubosomes. J. Colloid Sci. 623, 1142–1150 (2022). · DOI
  126. Tavano, R. et al. C1q-mediated complement activation and C3 opsonization trigger recognition of stealth poly (2-methyl-2-oxazoline)-coated silica nanoparticles by human phagocytes. ACS Nano 12, 5834–5847 (2018). · DOI · Paper page
  127. Hoogenboom, R. & Schlaad, H. Thermoresponsive poly (2-oxazoline)s, polypeptoids, and polypeptides. Polym. Chem. 8, 24–40 (2017). · DOI · Paper page
  128. Kang, D. D. et al. Engineering LNPs with polysarcosine lipids for mRNA delivery. Bioact. Mater. 37, 86–93 (2024).
  129. Bayraktutan, H. et al. Polysarcosine functionalised cationic polyesters efficiently deliver self-amplifying mRNA. Polym. Chem. 15, 1862–1876 (2024). · DOI
  130. Yao, X., Qi, C., Sun, C., Huo, F. & Jiang, X. Poly (ethylene glycol) alternatives in biomedical applications. Nano Today 48, 101738 (2023). · DOI
  131. Hara, E. et al. Pharmacokinetic change of nanoparticulate formulation ‘Lactosome’ on multiple administrations. Int. Immunopharmacol. 14, 261–266 (2012). · DOI
  132. Negwer, I. et al. Monitoring drug nanocarriers in human blood by near-infrared fluorescence correlation spectroscopy. Nat. Commun. 9, 5306 (2018). · DOI · Paper page
  133. Berger, M. et al. Poly (vinyl pyrrolidone) derivatives as PEG alternatives for stealth, non-toxic and less immunogenic siRNA-containing lipoplex delivery. J. Control. Rel. 361, 87–101 (2023). · DOI
  134. Wu, L.-P. et al. Dendrimer end-terminal motif-dependent evasion of human complement and complement activation through IgM hitchhiking. Nat. Commun. 12, 4858 (2021). · DOI
  135. Janaszewska, A. et al. Pyrrolidone modification prevents PAMAM dendrimers from activation of pro-inflammatory signaling pathways in human monocytes. Mol. Pharm. 15, 12–20 (2018). · DOI
  136. Axioti, E. et al. Glycerol- and diglycerol-based polyesters: evaluation of backbone alterations upon nano-formulation performance. Colloids Surf. B Biointerfaces 236, 113828 (2024). · DOI
  137. Soshee, A., Zürcher, S., Spencer, N. D., Halperin, A. & Nizak, C. General in vitro method to analyze the interactions of synthetic polymers with human antibody repertoires. Biomacromolecules 15, 113–121 (2014). · DOI
  138. Hulugalla, K. et al. Glycopolymeric nanoparticles enrich less immunogenic protein coronas, reduce mononuclear phagocyte clearance, and improve tumor delivery compared to PEGylated nanoparticles. ACS Nano 18, 30540–30560 (2024). · DOI · Paper page
  139. Hassanel, D. N. B. et al. Replacing poly (ethylene glycol) with RAFT lipopolymers in mRNA lipid nanoparticle systems for effective gene delivery. Int. J. Pharm. 665, 124695 (2024). · DOI
  140. Perrier, S. 50th anniversary perspective: RAFT polymerization. A user guide. Macromolecules 50, 7433–7447 (2017). · DOI · Paper page
  141. Safdar, A., Wang, P., Muhaymin, A., Nie, G. & Li, S. From bench to bedside: platelet biomimetic nanoparticles as a promising carriers for personalized drug delivery. J. Control. Rel. 373, 128–144 (2024). · DOI
  142. Li, S. et al. Protein precoating modulates biomolecular coronas and nanocapsule–immune cell interactions in human blood. J. Mater. Chem. B 10, 7607–7621 (2022). · DOI
  143. Gravan, P. et al. Exploring the impact of nanoparticle stealth coatings in cancer models: from PEGylation to cell membrane-coating nanotechnology. ACS Appl. Mater. Interfaces 16, 2058–2074 (2024). · DOI
  144. Hu, C.-M. J. et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature 526, 118–121 (2015). This article demonstrates the potential and advantages of membrane-cloaked nanomedicines. · DOI · Paper page
  145. Gao, C. et al. Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines. Nat. Commun. 11, 2622 (2020). · DOI · Paper page
  146. Wang, D. et al. Neuronal membrane-derived nanodiscs for broad-spectrum neurotoxin detoxification. ACS Nano 18, 25069–25080 (2024). · doi:10.1021/acsnano.4c06708
  147. Zhang, K. et al. Recent advances in cell membrane coated biomimetic nanomedicines: from laboratory research to clinical application. Preprint at Authorea https://doi.org/10.22541/au.171816032.20485120/v1 (2024). · doi:10.22541/au.171816032.20485120/v1
  148. Chan, M. H. et al. Integrated therapy platform of exosomal system: hybrid inorganic/organic nanoparticles with exosomes for cancer treatment. Nanoscale Horiz. 7, 352–367 (2022). · DOI
  149. Qin, X. et al. Spontaneously right‐side‐out‐orientated coupling‐driven ROS‐sensitive nanoparticles on cell membrane inner leaflet for efficient renovation in vascular endothelial injury. Adv. Sci. 10, 2205093 (2023). · DOI
  150. Fan, Z., Zhou, H., Li, P. Y., Speer, J. E. & Cheng, H. Structural elucidation of cell membrane-derived nanoparticles using molecular probes. J. Mater. Chem. B 2, 8231–8238 (2014). · DOI · Paper page
  151. Iqbal, H. et al. A bioinspired doxorubicin-carried albumin nanocage against aggressive cancer via systemic targeting of tumor and lymph node metastasis. J. Control. Rel. 372, 829–845 (2024). · DOI
  152. Gheibi Hayat, S. M., Bianconi, V., Pirro, M. & Sahebkar, A. Stealth functionalization of biomaterials and nanoparticles by CD47 mimicry. Int. J. Pharm. 569, 118628 (2019). · DOI
  153. Jalil, A. R., Tobin, M. P. & Discher, D. E. Suppressing or enhancing macrophage engulfment through the use of CD47 and related peptides. Bioconjug. Chem. 33, 1989–1995 (2022). · DOI
  154. Gheibi Hayat, S. M., Jaafari, M. R., Hatamipour, M., Jamialahmadi, T. & Sahebkar, A. Harnessing CD47 mimicry to inhibit phagocytic clearance and enhance anti-tumor efficacy of nanoliposomal doxorubicin. Expert Opin. Drug Deliv. 17, 1049–1058 (2020). · doi:10.1080/17425247.2020.1772749
  155. Spada, A., Emami, J., Tuszynski, J. A. & Lavasanifar, A. The uniqueness of albumin as a carrier in nanodrug delivery. Mol. Pharm. 18, 1862–1894 (2021). · DOI · Paper page
  156. Zheng, B. et al. Modulating the tumoral SPARC content to enhance albumin-based drug delivery for cancer therapy. J. Control. Rel. 366, 596–610 (2024). · DOI
  157. Capomaccio, R. et al. Determination of the structure and morphology of gold nanoparticle–HSA protein complexes. Nanoscale 7, 17653–17657 (2015). · DOI
  158. Zaleski, M. H. et al. Conjugation chemistry markedly impacts toxicity and biodistribution of targeted nanoparticles, mediated by complement activation. Adv. Mater. 37, 2409945 (2024). · DOI
  159. Blume, J. E. et al. Rapid, deep and precise profiling of the plasma proteome with multi-nanoparticle protein corona. Nat. Commun. 11, 3662 (2020). · DOI · Paper page
  160. Vaidya, A. et al. Expanding RNAi to kidneys, lungs, and spleen via selective organ targeting (SORT) siRNA lipid nanoparticles. Adv. Mater. 36, 2313791 (2024). This article reports a general approach to target lipid nanoparticles to different organs. · DOI
  161. Dilliard, S. A. et al. The interplay of quaternary ammonium lipid structure and protein corona on lung-specific mRNA delivery by selective organ targeting (SORT) nanoparticles. J. Control. Rel. 361, 361–372 (2023). · DOI
  162. Ding, T. et al. Reciprocal interaction with neutrophils facilitates cutaneous accumulation of liposomes. ACS Nano 18, 18769–18784 (2024). · DOI
  163. Luo, Z. et al. Neutrophil hitchhiking for drug delivery to the bone marrow. Nat. Nanotechnol. 18, 647–656 (2023). · DOI · Paper page
  164. Kuang, J. et al. Nanoparticles hitchhike on monocytes for glioblastoma treatment after low-dose radiotherapy. ACS Nano 17, 13333–13347 (2023). · DOI
  165. Mu, Q. et al. Ligustrazine nanoparticle hitchhiking on neutrophils for enhanced therapy of cerebral ischemia–reperfusion injury. Adv. Sci. 10, 2301348 (2023). · DOI
  166. Kim, S. A. et al. Protein-based nanocages for vaccine development. J. Control. Rel. 353, 767–791 (2023). · DOI
  167. Lee, E. J., Lee, N. K. & Kim, I. S. Bioengineered protein-based nanocage for drug delivery. Adv. Drug Deliv. Rev. 106, 157–171 (2016). · DOI · Paper page
  168. Brauer, D. D. et al. Systematic engineering of a protein nanocage for high-yield, site-specific modification. J. Am. Chem. Soc. 141, 3875–3884 (2019). · DOI · Paper page
  169. Kwon, S. & Giessen, T. W. Engineered protein nanocages for concurrent RNA and protein packaging in vivo. ACS Synth. Biol. 11, 3504–3515 (2022). · DOI · Paper page
  170. Yoo, J. D. et al. Designed ferritin nanocages displaying trimeric TRAIL and tumor-targeting peptides confer superior anti-tumor efficacy. Sci. Rep. 10, 19997 (2020). · DOI
  171. Zhang, J. et al. Cargo loading within ferritin nanocages in preparation for tumor-targeted delivery. Nat. Protoc. 16, 4878–4896 (2021). · DOI
  172. Ahn, B. et al. Four-fold channel-nicked human ferritin nanocages for active drug loading and pH-responsive drug release. Angew. Chem. Int. Ed. Engl. 57, 2909–2913 (2018). · DOI
  173. Divine, R. et al. Designed proteins assemble antibodies into modular nanocages. Science 372, eabd9994 (2021). · DOI · Paper page
  174. Yang, E. C. et al. Computational design of non-porous pH-responsive antibody nanoparticles. Nat. Struct. Mol. Biol. 31, 1404–1412 (2024). · DOI · Paper page
  175. Huddy, T. F. et al. Blueprinting extendable nanomaterials with standardized protein blocks. Nature 627, 898–904 (2024). This article reports the design of flexible protein building block system for the creation of new nanomedicines and nanomaterials. · DOI · Paper page
  176. Rennie, C. et al. In vivo behavior of systemically administered encapsulin protein nanocages and implications for their use in targeted drug delivery. Adv. Ther. 7, 2300360 (2024). · DOI
  177. Herrmann, I. K., Wood, M. J. A. & Fuhrmann, G. Extracellular vesicles as a next-generation drug delivery platform. Nat. Nanotechnol. 16, 748–759 (2021). · DOI · Paper page
  178. Cully, M. Exosome-based candidates move into the clinic. Nat. Rev. Drug Discov. 20, 6–7 (2021). · DOI · Paper page
  179. Wiklander, O. P. B. et al. Antibody-displaying extracellular vesicles for targeted cancer therapy. Nat. Biomed. Eng. 8, 1453–1468 (2024). · DOI
  180. Creeden, J. F. et al. Smart exosomes enhance PDAC targeted therapy. J. Control. Rel. 368, 413–429 (2024). · DOI
  181. Willms, E., Cabañas, C., Mäger, I., Wood, M. J. & Vader, P. Extracellular vesicle heterogeneity: subpopulations, isolation techniques, and diverse functions in cancer progression. Front. Immunol. 9, 738 (2018). · DOI · Paper page
  182. Gupta, D. et al. Quantification of extracellular vesicles in vitro and in vivo using sensitive bioluminescence imaging. J. Extracell. Vesicles 9, 1800222 (2020). · DOI · Paper page
  183. Whitehead, B. et al. Tumour exosomes display differential mechanical and complement activation properties dependent on malignant state: implications in endothelial leakiness. J. Extracell. Vesicles 4, 29685 (2015). · DOI · Paper page
  184. Xia, Y., Zhang, J., Liu, G. & Wolfram, J. Immunogenicity of extracellular vesicles. Adv. Mater. 36, 2403199 (2024). · DOI · Paper page
  185. Wu, J. P. et al. Reloadable multidrug capturing delivery system for targeted ischemic disease treatment. Sci. Transl. Med. 8, 365ra160 (2016). · DOI
  186. Chuang, K. H. et al. Endocytosis of PEGylated agents enhances cancer imaging and anticancer efficacy. Mol. Cancer Ther. 9, 1903–1912 (2010). · DOI
  187. Huang, W.-C. et al. Engineering chimeric receptors to investigate the size-and rigidity-dependent interaction of PEGylated nanoparticles with cells. ACS Nano 10, 648–662 (2016). · DOI
  188. Moles, E. et al. Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia. Sci. Transl. Med. 15, eabm1262 (2023). · DOI
  189. Kim, J. et al. Translational development of a tumor junction opening technology. Sci. Rep. 12, 7753 (2022). · doi:10.1038/s41598-022-11843-z
  190. Beyer, I. et al. Coadministration of epithelial junction opener JO-1 improves the efficacy and safety of chemotherapeutic drugs. Clin. Cancer Res. 18, 3340–3351 (2012). · DOI
  191. Chen, M. et al. A novel anti-tumor/anti-tumor-associated fibroblast/anti-mPEG tri-specific antibody to maximize the efficacy of mPEGylated nanomedicines against fibroblast-rich solid tumor. Biomater. Sci. 10, 202–215 (2022). · DOI
  192. Schiller, J. L., Marvin, A., McCallen, J. D. & Lai, S. K. Robust antigen-specific tuning of the nanoscale barrier properties of biogels using matrix-associating IgG and IgM antibodies. Acta Biomater. 89, 95–103 (2019). · DOI
  193. Schiller, J. L. et al. Antibody-mediated trapping in biological hydrogels is governed by sugar–sugar hydrogen bonds. Acta Biomater. 107, 91–101 (2020). · DOI
  194. Chithrani, B. D., Ghazani, A. A. & Chan, W. C. W. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 6, 662–668 (2006). · DOI · Paper page
  195. Kao, C. H. et al. One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles. Biomaterials 35, 9930–9940 (2014). · DOI
  196. Chen, H.-J. et al. Targeting and internalizing PEGylated nanodrugs to enhance the therapeutic efficacy of hematologic malignancies by anti-PEG bispecific antibody (mPEG × CD20). Cancer Nanotechnol. 14, 78 (2023). · DOI
  197. Cheng, W.-J. et al. Active tumoral/tumor environmental dual-targeting by non-covalently arming with trispecific antibodies or dual-bispecific antibodies on docetaxel-loaded mPEGylated nanocarriers to enhance chemotherapeutic efficacy and Minimize systemic toxicity. Int. J. Nanomed. 16, 4017–4030 (2021). · DOI
  198. Meng, J.-L. et al. pH-responsive polyethylene glycol engagers for enhanced brain delivery of PEGylated nanomedicine to treat glioblastoma. ACS Nano 19, 307–321 (2025). This article reports PEG engagers designed to increase nanoparticle delivery across the blood–brain barrier. · DOI
  199. Ho, K.-W. et al. Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity. J. Nanobiotechnol. 19, 1–12 (2021). · DOI
  200. Beishenaliev, A. et al. Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: a review. J. Control. Rel. 359, 268–286 (2023). · DOI

200 of 222 shown

Cited by

See all 113

Metadata

Authors
Chen, Y., Su, Y.-C., & Roffler, S. R.
Venue
Nature Reviews Bioengineering
Published
2025-06-10
Volume
3
Issue
9
Pages
742-760
ISSN
2731-6092
Cited by
113
References
21
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Polyethylene glycol immunogenicity in nanomedicine. https://app.cochat.ai/papers/10.1038/s44222-025-00321-6
The paper
Chen, Y., Su, Y.-C., & Roffler, S. R. (2025). Polyethylene glycol immunogenicity in nanomedicine. Nature Reviews Bioengineering. https://doi.org/10.1038/s44222-025-00321-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.